Every material Form 8-K COGNITION THERAPEUTICS INC has filed with the SEC since August 06, 2026, read and summarized by AI: what happened, the key figures, whether it reads positive or negative for shareholders, and how big a deal it is (impact 1-5). Newest first; each brief links to its own page and to the filing on SEC.gov.
Cognition Therapeutics received a Nasdaq deficiency letter on November 3, 2026, because its common stock has closed below the $1.00 minimum bid price for 30 consecutive business days. The company has until May 3, 2027, to regain compliance, and the letter has no immediate effect on its listing. Third-quarter results showed a smaller net loss than a year earlier, but the company reported $31.5 million in cash as of September 30, 2026.
Nasdaq letter dated November 3, 2026 cites a closing bid price below $1.00 for 30 consecutive business days; compliance deadline is May 3, 2027
Q3 2026 net loss was $4.1 million, or $(0.04) per share, versus $4.9 million, or $(0.06) per share, in Q3 2025
Research and development expenses rose to $5.1 million from $3.8 million, while general and administrative expenses fell to $2.3 million from $2.6 million
Cash and restricted cash equivalents were $31.5 million at September 30, 2026; the company estimates funding into the fourth quarter of 2027
Cognition Therapeutics said the FDA has aligned with it on key elements of a Phase 3 study of zervimesine in dementia with Lewy bodies, including patient selection, dose, duration and endpoints. The company is now completing a protocol for the planned registrational study, which the filing describes as covering a disease with no approved treatments. The filing contains no financial figures, so the update's effect on shareholders depends on the trial's future results and regulatory path.
Planned study will randomize participants with mild-to-moderate DLB to 100 mg once-daily oral zervimesine or placebo for nine months
Primary endpoint is the NPI-2 neuropsychiatric inventory measuring hallucinations and delusions
Key secondary endpoint is the ADCS-ADL scale, which evaluates effects on daily function
The announcement was made October 22, 2026, in a press release filed as Exhibit 99.1
Cognition Therapeutics reported a second-quarter 2026 net loss of $3.9 million, or $(0.04) per share, down from $6.7 million, or $(0.11) per share, a year earlier. Research and development expenses fell to $5.1 million from $11.5 million, while grant income also declined to $3.5 million from $7.1 million. The company said cash and restricted cash equivalents were $34.8 million at June 30, 2026, enough to fund operations into the fourth quarter of 2027.
Net loss for the quarter ended June 30, 2026 was $3.9 million, versus $6.7 million in the same period of 2025
Research and development expenses were $5.1 million, compared with $11.5 million a year earlier, driven by lower trial activity and compensation
Cash, cash equivalents, and restricted cash equivalents were $34.8 million at June 30, 2026; the company expects cash to last into the fourth quarter of 2027
The company plans to start a Phase 3 study in DLB psychosis in mid-2027 and received a Notice of Allowance for a zervimesine composition of matter patent
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.
Only material 8-Ks get a brief: results, deals, executive changes, restructuring, impairments, delisting notices, restatements, cybersecurity incidents and other disclosed events. Routine filings (vote results, exhibits only) are skipped. Every COGNITION THERAPEUTICS INC filing is on SEC EDGAR ↗. 8-K briefs of other companies →